OUR CLINICAL TRIALS

  • Status

  • Scenario

  • Patients population

  • Phase

  • Solti Program

  • Sites

  • Search

  • Reset


POLAR
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy Leer mas
POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women Leer mas
PROMETEO
Combination of Talimogene Laherparepvec with Atezolizumab in patients with residual breast cancer after standard neoadjuvant Leer mas
PROMETEO II
Palbociclib in combination with letrozole in patients with Hormone Receptor-positive/HER2-negative residual disease after standard neoadjuvant Leer mas
PUMA NER 10-005
A phase I/II trial of temsirolimus plus neratinib for patients with metastatic HER2-amplified or triple-negative Leer mas
RAD-001 (RADFEMARA)
A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to Leer mas
RESILIENCE (BAY 43-9006)
A phase III randomized, bouble blind, placebo-controlled trial comparing capecitabine plus sorafenib versus capecitabine plus Leer mas
RIBOLARIS
Ribociclib and endocrine therapy in neoadjuvant and adjuvant settings for clinically high-risk estrogen receptor-positive (ER+) Leer mas
SNAP
A randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer Leer mas